Fig. 4: Early-stage intervention with mRho ASO1 mitigates functional decline in Prph2Y141C/+ mice. | Nature Communications

Fig. 4: Early-stage intervention with mRho ASO1 mitigates functional decline in Prph2Y141C/+ mice.

From: Downregulation of rhodopsin is an effective therapeutic strategy in ameliorating peripherin-2-associated inherited retinal disorders

Fig. 4

A Schematic representation of the design for early-stage preclinical intervention studies. Created with BioRender.com released under a Creative Commons Attribution-Non-commercial-NoDervis 4.0 International license. B Representative waveforms of scotopic and photopic responses recorded 15 days after injection at P30. Mean ± SD maximum amplitudes of scotopic a-waves and scotopic b-wave (C) and photopic a-wave and b-wave amplitudes (D) of treated (3.125 µg mRho ASO1) and untreated contralateral control eyes recorded in preclinical early injection studies at ages P30, P60, and P90. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 by Mann-Whitney U test (PI-15: N = 51, PI-45: N = 34, and PI-75: N = 18).

Back to article page